Currently, there are active efforts to develop EZH2 inhibitors for cancer therapy, and our data suggest that they may also be useful to suppress epigenetic plasticity and its physiological consequences, such as metastasis and drug resistance. This evidence concerns the gene EZH2 and cancer.